News Category
Helus Pharma has named Michael Halstead as its new CEO, bringing extensive biopharmaceutical experience as the company advances its lead depression ca...
Website Rental Coaching, founded by Luke Van Der Veer, has expanded its local SEO training program to 14 countries, teaching entrepreneurs the 'Rank a...
Ireland has banned electroconvulsive therapy (ECT) for minors under its new Mental Health Act, a move hailed as a human rights advance, while advocate...
Helus Pharma has completed enrollment in its Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder, with res...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Helus Pharma has closed a $50 million underwritten public offering, with proceeds earmarked for clinical development of its novel serotonergic agonist...
The Japan Creator Support Fund has generated tangible international outcomes including awards, nominations, and co-productions across music, film, gam...
Helus Pharma has priced a $50 million public offering to fund Phase 3 trials for its depression treatment and other pipeline candidates.
Helus Pharma announced it has surpassed 86% enrollment in its Phase 3 APPROACH trial evaluating HLP003 for major depressive disorder, keeping the stud...
BOXABL has signed a distribution agreement with TerraCaita Limited to introduce its modular housing products across the UK and Ireland, marking a key ...
